Selected research
Market Outlook & Growth Opportunities
Global Gadopentetate Dimeglumine API Market Outlook and Growth Opportunities 2026
Market perspective
The global Gadopentetate Dimeglumine API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Gadopentetate Dimeglumine API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gadopentetate Dimeglumine API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gadopentetate Dimeglumine API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Gadopentetate Dimeglumine API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Gadopentetate Dimeglumine API market include Shanghai New Hualian Pharmaceutical, Seven Star Pharmaceutical, Guangdong Xianqiang Pharmaceutical, Beijing Beilu Pharmaceutical and Biophore, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Gadopentetate Dimeglumine API market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gadopentetate Dimeglumine API and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gadopentetate Dimeglumine API sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gadopentetate Dimeglumine API market size, projected growth trends, production technologies, key applications, and end-use industries.
Gadopentetate Dimeglumine API Segment by Company
Shanghai New Hualian Pharmaceutical
Seven Star Pharmaceutical
Guangdong Xianqiang Pharmaceutical
Beijing Beilu Pharmaceutical
Biophore
Gadopentetate Dimeglumine API Segment by Type
Purity ≥98%
Purity ≥99%
Gadopentetate Dimeglumine API Segment by Application
CNS Contrast Agent
Liver Contrast Agent
Others
Gadopentetate Dimeglumine API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Gadopentetate Dimeglumine API status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Gadopentetate Dimeglumine API market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Gadopentetate Dimeglumine API significant trends, drivers, influence factors in global and regions.
6. To analyze Gadopentetate Dimeglumine API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gadopentetate Dimeglumine API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gadopentetate Dimeglumine API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gadopentetate Dimeglumine API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gadopentetate Dimeglumine API market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gadopentetate Dimeglumine API industry.
Chapter 3: Detailed analysis of Gadopentetate Dimeglumine API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Gadopentetate Dimeglumine API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Gadopentetate Dimeglumine API in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity ≥98%
- Purity ≥99%
Applications
- CNS Contrast Agent
- Liver Contrast Agent
- Others
Companies covered
- Shanghai New Hualian Pharmaceutical
- Seven Star Pharmaceutical
- Guangdong Xianqiang Pharmaceutical
- Beijing Beilu Pharmaceutical
- Biophore
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Gadopentetate Dimeglumine API Sales Value (2021-2032)
- 1.2.2 Global Gadopentetate Dimeglumine API Sales Volume (2021-2032)
- 1.2.3 Global Gadopentetate Dimeglumine API Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Gadopentetate Dimeglumine API Market Dynamics
- 2.1 Gadopentetate Dimeglumine API Industry Trends
- 2.2 Gadopentetate Dimeglumine API Industry Drivers
- 2.3 Gadopentetate Dimeglumine API Industry Opportunities and Challenges
- 2.4 Gadopentetate Dimeglumine API Industry Restraints
3 Gadopentetate Dimeglumine API Market by Company
- 3.1 Global Gadopentetate Dimeglumine API Company Revenue Ranking in 2025
- 3.2 Global Gadopentetate Dimeglumine API Revenue by Company (2021-2026)
- 3.3 Global Gadopentetate Dimeglumine API Sales Volume by Company (2021-2026)
- 3.4 Global Gadopentetate Dimeglumine API Average Price by Company (2021-2026)
- 3.5 Global Gadopentetate Dimeglumine API Company Ranking (2024-2026)
- 3.6 Global Gadopentetate Dimeglumine API Company Manufacturing Base and Headquarters
- 3.7 Global Gadopentetate Dimeglumine API Company Product Type and Application
- 3.8 Global Gadopentetate Dimeglumine API Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Gadopentetate Dimeglumine API Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Gadopentetate Dimeglumine API Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Gadopentetate Dimeglumine API Market by Type
- 4.1 Gadopentetate Dimeglumine API Type Introduction
- 4.1.1 Purity ≥98%
- 4.1.2 Purity ≥99%
- 4.2 Global Gadopentetate Dimeglumine API Sales Volume by Type
- 4.2.1 Global Gadopentetate Dimeglumine API Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gadopentetate Dimeglumine API Sales Volume by Type (2021-2032)
- 4.2.3 Global Gadopentetate Dimeglumine API Sales Volume Share by Type (2021-2032)
- 4.3 Global Gadopentetate Dimeglumine API Sales Value by Type
- 4.3.1 Global Gadopentetate Dimeglumine API Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Gadopentetate Dimeglumine API Sales Value by Type (2021-2032)
- 4.3.3 Global Gadopentetate Dimeglumine API Sales Value Share by Type (2021-2032)
5 Gadopentetate Dimeglumine API Market by Application
- 5.1 Gadopentetate Dimeglumine API Application Introduction
- 5.1.1 CNS Contrast Agent
- 5.1.2 Liver Contrast Agent
- 5.1.3 Others
- 5.2 Global Gadopentetate Dimeglumine API Sales Volume by Application
- 5.2.1 Global Gadopentetate Dimeglumine API Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gadopentetate Dimeglumine API Sales Volume by Application (2021-2032)
- 5.2.3 Global Gadopentetate Dimeglumine API Sales Volume Share by Application (2021-2032)
- 5.3 Global Gadopentetate Dimeglumine API Sales Value by Application
- 5.3.1 Global Gadopentetate Dimeglumine API Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Gadopentetate Dimeglumine API Sales Value by Application (2021-2032)
- 5.3.3 Global Gadopentetate Dimeglumine API Sales Value Share by Application (2021-2032)
6 Gadopentetate Dimeglumine API Regional Sales and Value Analysis
- 6.1 Global Gadopentetate Dimeglumine API Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gadopentetate Dimeglumine API Sales by Region (2021-2032)
- 6.2.1 Global Gadopentetate Dimeglumine API Sales by Region: 2021-2026
- 6.2.2 Global Gadopentetate Dimeglumine API Sales by Region (2027-2032)
- 6.3 Global Gadopentetate Dimeglumine API Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Gadopentetate Dimeglumine API Sales Value by Region (2021-2032)
- 6.4.1 Global Gadopentetate Dimeglumine API Sales Value by Region: 2021-2026
- 6.4.2 Global Gadopentetate Dimeglumine API Sales Value by Region (2027-2032)
- 6.5 Global Gadopentetate Dimeglumine API Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Gadopentetate Dimeglumine API Sales Value (2021-2032)
- 6.6.2 North America Gadopentetate Dimeglumine API Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Gadopentetate Dimeglumine API Sales Value (2021-2032)
- 6.7.2 Europe Gadopentetate Dimeglumine API Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Gadopentetate Dimeglumine API Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Gadopentetate Dimeglumine API Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Gadopentetate Dimeglumine API Sales Value (2021-2032)
- 6.9.2 South America Gadopentetate Dimeglumine API Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Gadopentetate Dimeglumine API Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Gadopentetate Dimeglumine API Sales Value Share by Country, 2025 VS 2032
7 Gadopentetate Dimeglumine API Country-level Sales and Value Analysis
- 7.1 Global Gadopentetate Dimeglumine API Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Gadopentetate Dimeglumine API Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Gadopentetate Dimeglumine API Sales by Country (2021-2032)
- 7.3.1 Global Gadopentetate Dimeglumine API Sales by Country (2021-2026)
- 7.3.2 Global Gadopentetate Dimeglumine API Sales by Country (2027-2032)
- 7.4 Global Gadopentetate Dimeglumine API Sales Value by Country (2021-2032)
- 7.4.1 Global Gadopentetate Dimeglumine API Sales Value by Country (2021-2026)
- 7.4.2 Global Gadopentetate Dimeglumine API Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.9.2 France Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.16.2 China Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.19.2 India Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Gadopentetate Dimeglumine API Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Gadopentetate Dimeglumine API Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Gadopentetate Dimeglumine API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Shanghai New Hualian Pharmaceutical
- 8.1.1 Shanghai New Hualian Pharmaceutical Company Information
- 8.1.2 Shanghai New Hualian Pharmaceutical Business Overview
- 8.1.3 Shanghai New Hualian Pharmaceutical Gadopentetate Dimeglumine API Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Shanghai New Hualian Pharmaceutical Gadopentetate Dimeglumine API Product Portfolio
- 8.1.5 Shanghai New Hualian Pharmaceutical Recent Developments
- 8.2 Seven Star Pharmaceutical
- 8.2.1 Seven Star Pharmaceutical Company Information
- 8.2.2 Seven Star Pharmaceutical Business Overview
- 8.2.3 Seven Star Pharmaceutical Gadopentetate Dimeglumine API Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Seven Star Pharmaceutical Gadopentetate Dimeglumine API Product Portfolio
- 8.2.5 Seven Star Pharmaceutical Recent Developments
- 8.3 Guangdong Xianqiang Pharmaceutical
- 8.3.1 Guangdong Xianqiang Pharmaceutical Company Information
- 8.3.2 Guangdong Xianqiang Pharmaceutical Business Overview
- 8.3.3 Guangdong Xianqiang Pharmaceutical Gadopentetate Dimeglumine API Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Guangdong Xianqiang Pharmaceutical Gadopentetate Dimeglumine API Product Portfolio
- 8.3.5 Guangdong Xianqiang Pharmaceutical Recent Developments
- 8.4 Beijing Beilu Pharmaceutical
- 8.4.1 Beijing Beilu Pharmaceutical Company Information
- 8.4.2 Beijing Beilu Pharmaceutical Business Overview
- 8.4.3 Beijing Beilu Pharmaceutical Gadopentetate Dimeglumine API Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Beijing Beilu Pharmaceutical Gadopentetate Dimeglumine API Product Portfolio
- 8.4.5 Beijing Beilu Pharmaceutical Recent Developments
- 8.5 Biophore
- 8.5.1 Biophore Company Information
- 8.5.2 Biophore Business Overview
- 8.5.3 Biophore Gadopentetate Dimeglumine API Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Biophore Gadopentetate Dimeglumine API Product Portfolio
- 8.5.5 Biophore Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Gadopentetate Dimeglumine API Value Chain Analysis
- 9.1.1 Gadopentetate Dimeglumine API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gadopentetate Dimeglumine API Sales Mode & Process
- 9.2 Gadopentetate Dimeglumine API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gadopentetate Dimeglumine API Distributors
- 9.2.3 Gadopentetate Dimeglumine API Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst